FDA Hearing. What FDA Failed to Disclose: 1991, 2006.
AHRP Testimony presented by Vera Sharav, December 2006. PowerPoint slides (843 kb file).
AHRP Testimony presented by Vera Sharav, December 2006. PowerPoint slides (843 kb file).
FDA Slaps Pfizer on Zoloft Ads After AHRP Files Complaint Sat, 07 May 2005 On November 4, 2004, AHRP filed a complaint with the FDA about a two page Pfizer advertisement for its SSRI antidepressant, Zoloft. The ad appeared in The New York Times Magazine in October 2004, but Pfizer…
AHRP Correspondence with Government Agencies related link: FDA response to AHRP procedural questions (FDA sham conflicts of interest policy) FDA re: supression of SSRI evidence ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) 142 West End Ave, Suite 28P New York, NY 10023 https://ahrp.org Tel: 212-595-8974 e-mail: October 29, 2003 To: Thomas…
http://www.nj.com/news/ledger/index.ssf?/base/news-20/1108104141208160.xml Star-Ledger 14 deaths force halt to drug in Canada Hyperactivity remedy called threat to kids Friday, February 11, 2005 BY CAROL ANN CAMPBELL Safety concerns have clouded the future of another blockbuster medication, this one a hyperactivity drug prescribed to 700,000 Americans, most of them children. Health officials in…
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has released an interim report about the near fatal clinical trial of the monoclonal antibody, TGN1412, stating:
NIH Chief Calls for Ethics Summit to address Conflicts of Interest in Medical Research – LA Times Mon, 14 Feb 2005 AHRP applauds Dr. Elias Zerhouni, director of the National Institutes of Health, for stepping up to the plate as a leader of an agency that will award about $21…
Dr. E. Jane Costello, a professor of psychiatry and behavioral sciences at Duke University, acknowledges: “The system of diagnosis is still 200 to 300 years behind other branches of medicine.” Psychiatry also fails to be guided by an evidence-based positive benefit / risk assessment of its prescribed treatments.